Download PDF
Pharmacopsychiatry 2017; 50(06): 264-269
DOI: 10.1055/s-0043-113828
Original Paper

Patients’ Knowledge about Prescribed Antipsychotics and Medication Adherence in Schizophrenia: A Cross-Sectional Survey

Nobuhiro Nagai
1   Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
,
Hideaki Tani
1   Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
,
Takefumi Suzuki
1   Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
2   Inokashira Hospital, Tokyo, Japan
,
Saeko Ikai
1   Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
,
Philip Gerretsen
3   Multimodal Imaging Group - Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
4   Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Canada
,
Masaru Mimura
1   Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
,
Hiroyuki Uchida
1   Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
4   Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Canada
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Corrected by:

Correction: Patients’ Knowledge about Prescribed Antipsychotics and Medication Adherence in Schizophrenia: A Cross-Sectional SurveyPharmacopsychiatry 2017; 50(06): e1-e1
DOI: 10.1055/a-1274-1002

Abstract

Introduction Data on the knowledge about antipsychotic medications prescribed in patients with schizophrenia are very limited. Moreover, it remains unclear how patients’ knowledge about prescribed antipsychotics affects medication adherence.

Methods ighty-one Japanese outpatients with schizophrenia according to the International Classification of Diseases, 10th edition, were included. Patients’ knowledge of the primary antipsychotics prescribed to them in terms of therapeutic effects, type, and implicated neurotransmitters was assessed with a multiple-choice questionnaire developed for this study. Medication possession ratios (MPRs) were compared between patients who answered correctly and those who did not in each category.

Results The percentages of subjects who answered correctly regarding antipsychotic effects, type, and implicated neurotransmitters were low at 30.9%, 30.9%, and 7.4%, respectively. No differences were found in MPRs between subjects who answered correctly and those who did not.

Discussion Our preliminary results indicate that patients lack knowledge about their antipsychotic medications. More concerning, they suggest that knowledge about prescribed antipsychotics may not directly translate into actual medication adherence in patients with schizophrenia.

Key words

adherence - antipsychotics - knowledge - medication - schizophrenia


Publication History

Article published online:
04 July 2017

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Leucht S, Barnes TR, Kissling W. et al. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-1222
    CrossrefPubMedGoogle Scholar
  • 2 Uchida H, Suzuki T, Takeuchi H. et al. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: Meta-analysis. Schizophrenia Bull 2011; 37: 788-799
    CrossrefPubMedGoogle Scholar
  • 3 Suzuki T, Uchida H, Takeuchi H. et al. A review on schizophrenia and relapse – a quest for user-friendly psychopharmacotherapy. Hum Psychopharmacol 2014; 29: 414-426
    CrossrefPubMedGoogle Scholar
  • 4 Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: Our patients can do better. J Clin Psychiatry 2003; 64: 1308-1315
    CrossrefPubMedGoogle Scholar
  • 5 Thieda P, Beard S, Richter A. et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54: 508-516
    CrossrefPubMedGoogle Scholar
  • 6 Gilmer TP, Dolder CR, Lacro JP. et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161: 692-699
    CrossrefPubMedGoogle Scholar
  • 7 Clary C, Dever A, Schweizer E. Psychiatric inpatients' knowledge of medication at hospital discharge. Hosp Community Psychiatry 1992; 43: 140-144
    PubMedGoogle Scholar
  • 8 Macpherson R, Double DB, Rowlands RP. et al. Long-term psychiatric patients' understanding of neuroleptic medication. Hosp Community Psychiatry 1993; 44: 71-73
    PubMedGoogle Scholar
  • 9 Tempier R. Long-term psychiatric patients' knowledge about their medication. Psychiatr Serv 1996; 47: 1385-1387
    CrossrefPubMedGoogle Scholar
  • 10 Benner JS, Chapman RH, Petrilla AA. et al. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm 2009; 66: 1471-1477
    CrossrefPubMedGoogle Scholar
  • 11 Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011; 65: 314-322
    CrossrefPubMedGoogle Scholar
  • 12 Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol 2014; 17: 1083-1093
    CrossrefPubMedGoogle Scholar
  • 13 Inagaki A, Inada T, Fujii Y. Dose Equivalents of Psychotropic Drugs. Seiwa Publishers; Tokyo: 1999
    Google Scholar
  • 14 Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XXI: Dose equivalence of novel antipsychotics. Jpn J Clin Psychopharmacol 2008; 11: 887-890
    PubMedGoogle Scholar
  • 15 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
    CrossrefPubMedGoogle Scholar
  • 16 Endicott J, Spitzer RL, Fleiss JL. et al. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766-771
    CrossrefPubMedGoogle Scholar
  • 17 Gerretsen P, Remington G, Borlido C. et al. The VAGUS insight into psychosis scale – self-report and clinician-rated versions. Psychiatry Res 2014; 220: 1084-1089
    CrossrefPubMedGoogle Scholar
  • 18 Valenstein M, Copeland LA, Blow FC. et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002; 40: 630-639
    CrossrefPubMedGoogle Scholar
  • 19 Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychol Med. 1983; 13: 177-183
    CrossrefPubMedGoogle Scholar
  • 20 Miyata R. Drug compliance in schizophrenia. Jpn J Clin Psychiatry 1999; 28: 265-275
    PubMedGoogle Scholar
  • 21 Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24: 67-74
    CrossrefPubMedGoogle Scholar
  • 22 Owashi T. Assessment methods of compliance and adherence. Jpn J Clin Psychiatry 2010; 39: 755-773
    PubMedGoogle Scholar
  • 23 Valenstein M, Ganoczy D, McCarthy JF. et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: A retrospective review. J Clin Psychiatry 2006; 67: 1542-1550
    CrossrefPubMedGoogle Scholar
  • 24 Kuwabara H, Saito Y, Mahlich J. Adherence and rehospitalizations in patients with schizophrenia: Evidence from Japanese claims data. Neuropsychiatr Dis Treat 2015; 11: 935-940
    PubMedGoogle Scholar
  • 25 Bosch-Lenders D, Maessen DW, Stoffers HE. et al. Factors associated with appropriate knowledge of the indications for prescribed drugs among community-dwelling older patients with polypharmacy. Age Ageing 2016; 45: 402-408
    CrossrefPubMedGoogle Scholar
  • 26 Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2011; 6: CD002831
    CrossrefPubMedGoogle Scholar
  • 27 Pitschel-Walz G, Bäuml J, Bender W. et al. Psychoeducation and compliance in the treatment of schizophrenia: Results of the Munich Psychosis Information Project Study. J Clin Psychiatry 2006; 67: 443-452
    CrossrefPubMedGoogle Scholar
  • 28 Rummel-Kluge C, Pitschel-Walz G, Kissling W. A fast, implementable psychoeducation program for schizophrenia. Psychiatr Serv 2007; 58: 1226
    CrossrefPubMedGoogle Scholar
  • 29 Froböse T, Bäuml J, Jahn T. et al. Knowledge gain by psychoeducation for patients with schizophrenia: Associations with sociodemographic data, psychopathology, insight and global neurocognitive performance. Int J Clin Psychiatry Ment Health 2014; 2: 111-121
    CrossrefPubMedGoogle Scholar
  • 30 Pijnenborg GH, van Donkersgoed RJ, David AS. et al. Changes in insight during treatment for psychotic disorders: A meta-analysis. Schizophr Res 2013; 144: 109-117
    CrossrefPubMedGoogle Scholar
  • 31 Haynes RB, Ackloo E, Sahota N. et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 11: CD000011
    PubMedGoogle Scholar
  • 32 Reichhart T, Pitschel-Walz G, Kissling W. et al. Gender differences in patient and caregiver psychoeducation for schizophrenia. Eur Psychiatry 2010; 25: 39-46
    CrossrefPubMedGoogle Scholar
  • 33 Minamisawa A, Suzuki T, Watanabe K. et al. Patient's trust in their psychiatrist: A cross-sectional survey. Eur Arch Psychiatry Clin Neurosci 2011; 261: 603-608
    CrossrefPubMedGoogle Scholar
  • 34 Misdrahi D, Petit M, Blanc O. et al. The influence of therapeutic alliance and insight on medication adherence in schizophrenia. Nord J Psychiatry 2012; 66: 49-54
    CrossrefPubMedGoogle Scholar
  • 35 Jahn T, Pitschel-Walz G, Gsottschneider A. et al. Neurocognitive prediction of illness knowledge after psychoeducation in schizophrenia: results from the Munich COGPIP study. Psychol Med 2011; 41: 533-544
    CrossrefPubMedGoogle Scholar
  • 36 Tsutsumi C, Uchida H, Suzuki T. et al. The evolution of antipsychotic switch and polypharmacy in natural practice – a longitudinal perspective. Schizophr Res. 2011; 130: 40-46
    CrossrefPubMedGoogle Scholar
  • 37 Shinfuku M, Uchida H, Tsutsumi C. et al. How psychotropic polypharmacy in schizophrenia begins: A longitudinal perspective. Pharmacopsychiatry 2012; 45: 133-137
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Uchida H, Suzuki T, Mamo DC. et al. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: A survey of 1,418 patients in Japan. Am J Geriatr Psychiatry 2008; 16: 584-593
    CrossrefPubMedGoogle Scholar